INS and type 1 diabetes mellitus: Inducing Remission in New-Onset T1D with alefacept (T1DAL; Rigby et al, 2013) study in stage 3 T1D patients (alefacept: 33 patients, placebo: 16 patients) showed a significant increase in the mean 4-hour C-peptide AUC (P = .019) and reduction in insulin demand (P = .02) after 12 months of treatment with no difference in HbA1c and mean 2-hour C-peptide AUC.